Cardiotoxicity from chemotherapy remains a critical concern, particularly with agents like doxorubicin and trastuzumab. Pre-existing cardiovascular conditions elevate this risk. Proactive monitoring, dosage adjustments, and cardio-oncology collaboration are vital for mitigating cardiac damage during treatment, ensuring both oncologic efficacy and long-term cardiac function.